Business
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021. Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update. Conference Call Information: Date:Wednesday, November 10Time:8:30 am Eastern TimeDomestic Dial-in:(844) 615-6509International Dial-in:(918) 922-3148Conference ID:5783655Webcast:https://edge.media-server.com/mmc/p/zgrrmubx About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Investor and Media Contact:Will BrownChief Financial OfficerPhone: [email protected] \nSource: Altimmune, Inc","length":3526,"tagName":"div"}]